Skip to main content
Top

11-29-2012 | Post-transplant diabetes mellitus | Review | Article

Management of Post-Transplant Diabetes

Journal: Current Diabetes Reports

Authors: Ashley Therasse, Amisha Wallia, Mark E. Molitch

Publisher: Current Science Inc.

Abstract

New onset diabetes mellitus after transplant (NODAT) refers to the development of diabetes post-transplant in previously non-diabetic patients and is associated with increased rates of acute transplant rejection, infection, late cardiovascular events, and decreased survival. NODAT is primarily due to the immunosuppressive drug regimen but the standard predisposing risk factors for diabetes also pertain. NODAT is diagnosed by the standard ADA criteria, once prednisone doses are less than 10 mg per day and in the absence of acute illness. Sulfonylureas, metformin, DPP-4 inhibitors, GLP-1 agonists, and insulin can be used in treatment, but when there is impaired kidney or hepatic function, special precautions are necessary. In addition, those drugs interacting with P450 enzymes require additional consideration because of possible interaction with immunosuppressive drug metabolism.
Literature
1.
Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583–92.PubMedCrossRef
2.••
Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–24. This article presents the most recent guidlines regarding the diagnosis and treatment of new onset diabetes after solid organ transplant.PubMedCrossRef
3.
Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):A7, e1–420.
4.
Ganji MR, Charkhchian M, Hakemi M, et al. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc. 2007;39:852–4.PubMedCrossRef
5.
Hosseini MS, Nemati E, Pourfarziani V, et al. Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant. 2007;12:23–6.PubMed
6.
Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62:1440–6.PubMedCrossRef
7.
Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590–8.PubMedCrossRef
8.
American Diabetes A. Standards of Medical Care in Diabetes–2012. Diabetes Care. 2012;35 Suppl 1:S11–63. This article covers the most recent guidelines for the diagnosis and management of type 2 diabetes.
9.
van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81–93.PubMedCrossRef
10.
Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31.PubMedCrossRef
11.•
Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97:16–38. This article provides recommendations for the inpatient management of hyperglycemia in non-ICU patients.PubMedCrossRef
12.
Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415–21.PubMedCrossRef
13.
Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59:732–7.PubMedCrossRef
14.
Salvadori M, Bertoni E, Rosati A, Zanazzi M. Post-transplant diabetes mellitus. J Nephrol. 2003;16:626–34.PubMed
15.
Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era–an analysis of risk factors. Transplantation. 1991;51:343–7.PubMedCrossRef
16.
Depczynski B, Daly B, Campbell LV, et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17:15–9.PubMedCrossRef
17.
Baid S, Cosimi AB, Farrell ML, et al. Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72:1066–72.PubMedCrossRef
18.
Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374–80.PubMedCrossRef
19.
Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis. 2004;43:953–65.PubMedCrossRef
20.
Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation. 2011;91:334–41.PubMedCrossRef
21.
Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–83.PubMedCrossRef
22.
Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol. 1997;8:294–301.PubMed
23.
Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775–82.PubMedCrossRef
24.
Rostambeigi N, Lanza IR, Dzeja PP, et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction. Transplantation. 2011;91:615–23.PubMedCrossRef
25.
Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–95.PubMedCrossRef
26.
Xu X, Ling Q, He ZL, et al. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int. 2008;7:465–70.PubMed
27.
Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68:396–402.PubMedCrossRef
28.
Penninga L, Møller CH, Gustafsson F, et al. Tacrolimus vs cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010;66:1177–87.PubMedCrossRef
29.
Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int. 2008;21:146–51.PubMed
30.
Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc. 2011;43:1583–92.PubMedCrossRef
31.
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3 Suppl):7S–14.PubMedCrossRef
32.••
Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2006;81:335–41. This trial demonstrated that older age, obesity, steroid pulse therapy, and tacrolimus use all increased the risk of developing NODAT.PubMedCrossRef
33.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCrossRef
34.
Rassias AJ, Marrin CA, Arruda J, et al. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg. 1999;88:1011–6.PubMed
35.
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3–4):259–65.PubMedCrossRef
36.
van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–67.PubMedCrossRef
37.
Finfer S, Chittock DR, Su SY, et al. Intensive vs conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.PubMedCrossRef
38.
Ammori JB, Sigakis M, Englesbe MJ, et al. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res. 2007;140:227–33.PubMedCrossRef
39.
Thomas MC, Mathew TH, Russ GR, et al. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.PubMedCrossRef
40.
Thomas MC, Moran J, Mathew TH, et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000;1:1.PubMedCrossRef
41.
Wallia A, Parikh ND, Molitch ME, et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222–6.PubMedCrossRef
42.
Wallia A, Parikh ND, O'Shea-Mahler E, et al. Glycemic control by a Glucose Management Service and infection rates following liver transplantation. Endocr Pract. 2011;17:546–51.PubMedCrossRef
43.
Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108–18.PubMedCrossRef
44.
Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–7.PubMedCrossRef
45.
Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094–102.PubMed
46.
Frid A, Sterner GN, Londahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291–3.PubMedCrossRef
47.
Rachmani R, Slavachevski I, Levi Z, et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13:428–33.PubMedCrossRef
48.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.PubMed
49.
Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380–3.PubMedCrossRef
50.
Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology. 2010;15:412–8.PubMedCrossRef
51.
Jonsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol. 1998;53:429–35.PubMedCrossRef
52.
Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–24.PubMedCrossRef
53.
Asplund K, Wiholm BE, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med. 1991;8:726–31.PubMedCrossRef
54.
Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59:191–4.PubMedCrossRef
55.
Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60:90–5.PubMed
56.
Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147–52.PubMedCrossRef
57.
Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886–91.PubMedCrossRef
58.
Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2012;98:408–14.
59.
Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129–37.PubMedCrossRef
60.
Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:26298:408-14.9.
61.
Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol. 2012;303:F681–8.CrossRef
62.
Zhai W, Cardell M, De Meester I, et al. Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. J Heart Lung Transplant. 2007;26:174–80.PubMedCrossRef
63.
Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349–54.PubMedCrossRef
64.
Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012;51:411–27.PubMedCrossRef
65.
Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317–27.PubMedCrossRef
66.
Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol. 2008;66:568–9.PubMedCrossRef
67.
Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32:e22–3.PubMedCrossRef
68.
Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metabol. 2012;14:596–600.CrossRef
69.
Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898–905.PubMedCrossRef
70.
Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83:24–8.PubMedCrossRef
71.
Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86:36–45.PubMedCrossRef
72.
Rickels MR, Mueller R, Markmann JF, Naji A. Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94:181–9.PubMedCrossRef
73.
Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19:291–8.PubMedCrossRef
74.
Muhlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care. 1991;14:344–6.PubMedCrossRef
75.
Hasslacher C, Wittmann W. Severe hypoglycemia in diabetics with impaired renal function. Dtsch Med Wochenschr. 2003;128:253–6.PubMedCrossRef
76.
Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4.PubMedCrossRef
77.
Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199–206.PubMedCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »